300354-95-4

Basic information

• Product Name: Benzeneacetic acid, a-(cyclopentylmethyl)-4-(methylsulfonyl)-
• CAS NO: 300354-95-4
• Molecular Formula: C15H20O4S
• Molecular Weight: 296.387
• Mol File: 300354-95-4.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: Benzeneacetic acid, a-(cyclopentylmethyl)-4-(methylsulfonyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzeneacetic acid, a-(cyclopentylmethyl)-4-(methylsulfonyl)-(300354-95-4)
• EPA Substance Registry System: Benzeneacetic acid, a-(cyclopentylmethyl)-4-(methylsulfonyl)-(300354-95-4)

Safety Data

• Hazardous Substances Data: 300354-95-4(Hazardous Substances Data)

Upstream product

• 300355-05-9 3-cyclopentyl-2-(4-methylsulfanyl-phenyl)propionic acid 
• 27935-87-1 cyclopentylmethyl Iodide 
• 90536-66-6 4-(methylsulfonyl)phenylacetic acid 
• 300355-19-5 3-cyclopentyl-2-(4-methanesulfonyl-phenyl)propionic acid methyl ester 
• 300355-18-4 (4-methanesulfonyl-phenyl)-acetic acid methyl ester 

Downstream Products

• 588939-98-4 N-(5-bromo-thiazol-2-yl)-3-cyclopentyl-2(R)-(4-methanesulfonyl-phenyl)-propionamide 
• 705980-78-5 3-cyclopentyl-2-(4-methanesulfonyl-phenyl)-propionyl chloride 
• 1348539-58-1 C₁₉H₂₃N₃O₃S 
• 1393926-49-2 C₁₈H₂₁N₃O₅S₂ 
• 588939-85-9 C₁₈H₂₁ClN₂O₃S₂ 
• 300353-00-8 2-[3-cyclopentyl-2-(4-methanesulfonylphenyl)propionylamino]thiazole-4-carboxylic acid ethyl ester 
• 1393926-50-5 C₁₉H₂₃N₃O₃S 
• 1080059-89-7 3-cyclopentyl-N-(5-isopropylisoxazol-4-yl)-2-[4-(methylsulfonyl)phenyl]propanamide 
• 1080059-71-7 3-cyclopentyl-N-methoxy-N-methyl-2-[4-(methylsulfonyl)phenyl]propanamide 
• 588940-26-5 2-[3-cyclopentyl-2-(4-methanesulfonyl-phenyl)-propionylamino]-thiazole-5-carboxylic acid ethyl ester 
• 300352-96-9 Ro 28-0450 

Relevant articles and documents

Discovery, structure-activity relationships, pharmacokinetics, and efficacy of glucokinase activator (2 R)-3-cyclopentyl-2-(4-methanesulfonylphenyl)-N- thiazol-2-yl-propionamide (RO0281675)

Glucokinase (GK) is a glucose sensor that couples glucose metabolism to insulin release. The important role of GK in maintaining glucose homeostasis is illustrated in patients with GK mutations. In this publication, identification of the hit molecule 1 and its SAR development, which led to the discovery of potent allosteric GK activators 9a and 21a, is described. Compound 21a (RO0281675) was used to validate the clinical relevance of targeting GK to treat type 2 diabetes.

HETEROAROMATIC GLUCOKINASE ACTIVATORS

The present invention describes 2,3-di-substituted N-heteroaromatic propionamides, of Formula (I) wherein the substitution at the 3-position is an optionally substituted phenyl ring and the substitution at the 2-position is an alkyl or cycloalkyl group; p

HETEROAROMATIC GLUCOKINASE ACTIVATORS

-